Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xencor Inc. (XNCR)
:XNCR
Holding XNCR?
Track your performance easily
Earnings Data
Report Date
Mar 03, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.78Last Year’s EPS
-0.31Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 05, 2018
|% Change Since: -15.17%
|Next Earnings Date:Aug 06, 2018
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant pipeline progress and a strong financial position. However, safety concerns with vudalimab and a strategic pause on XmAb564 development were noted.Company Guidance
During Xencor's fourth-quarter 2023 earnings call, the company provided comprehensive guidance on its clinical pipeline and financial outlook. They highlighted a significant focus on the development of bispecific T-cell engagers for solid tumors, including XmAb819 and XmAb808, with ongoing Phase I studies in renal cell carcinoma and prostate cancer, respectively. Vudalimab, a key candidate, showed promising monotherapy results in heavily pre-treated metastatic castrate-resistant prostate cancer patients, with a RECIST response rate of 35% and a PSA90 rate of 25%. Financially, Xencor bolstered its balance sheet through the partial monetization of Ultomiris and Monjuvi royalties, ending 2023 with $697 million, ensuring operational runway until 2027. The company's 2024 priorities include advancing its solid tumor bispecific programs and selecting the next IND candidate, while maintaining a strategic focus on T-cell engager discovery and development.Strong Financial Position
Xencor ended 2023 with $697 million, providing runway into 2027 due to robust milestone and royalty revenues.
Clinical Pipeline Progress
Significant advancement in bispecific T-cell engagers for solid tumors, including vudalimab in prostate and lung cancer.
Encouraging Vudalimab Data
The prostate cancer monotherapy cohort showed a RECIST response rate of 35% and a disease control rate of 50%.
XmAb Bispecific Technology Development
XmAb bispecific technology shows promise for solid tumor selectivity, with ongoing studies in renal and prostate cancer.
---
XNCR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
XNCR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $22.68 | $23.18 | +2.20% |
| Aug 05, 2024 | $17.78 | $17.85 | +0.39% |
| May 09, 2024 | $23.54 | $22.48 | -4.50% |
| Feb 27, 2024 | $26.52 | $22.79 | -14.06% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Xencor Inc. (XNCR) report earnings?
Xencor Inc. (XNCR) is schdueled to report earning on Mar 03, 2025, TBA Not Confirmed.
What is Xencor Inc. (XNCR) earnings time?
Xencor Inc. (XNCR) earnings time is at Mar 03, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XNCR EPS forecast?
XNCR EPS forecast for the fiscal quarter 2024 (Q4) is -0.78.
---